About Basilea
Basilea is a company based in Basel (Switzerland) founded in 1999. It operates as a Professional Services and Licensing Model. The company has 164 employees. Basilea offers products and services including Cresemba, Zevtera, Ceftibuten-Ledaborbactam, Fosmanogepix, and BAL2062. Basilea operates in a competitive market with competitors including Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
- Headquarter Basel, Switzerland
- Employees 164
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website basilea.com
- Social LinkedIn
- Legal Name Basilea Pharmaceutica Ag
- Annual Revenue$293.16 M (USD)11.43as on Dec 31, 2025
- Net Profit$50.76 M (USD)-48.14as on Dec 31, 2025
- EBITDA$69.71 M (USD)-14.6as on Dec 31, 2025
- Latest Funding Round$6M (USD), Grant
Feb 2026
- InvestorsCARB-X
& 2 more
- Employee Count164
Products & Services of Basilea
Basilea offers a comprehensive portfolio of products and services, including Cresemba, Zevtera, Ceftibuten-Ledaborbactam, Fosmanogepix, and BAL2062.
Cresemba is developed for treating fungal infections effectively.
Zevtera is formulated to combat severe bacterial infections.
Ceftibuten-Ledaborbactam is researched for oral antibiotic treatment solutions.
Fosmanogepix is advanced for novel antifungal therapy options.
BAL2062 is developed as a new antifungal treatment.
Funding Insights of Basilea
- Total Rounds 8
- Last Round Grant — $6M
- Investors Count 3
All 8 funding rounds of Basilea with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $6M | Grant | – | – | |
| Dec 2024 | $7.3M | Grant | – | – | |
| Apr 2024 | $900,000 | Grant | – | – | |
| Aug 2021 | $4.3M | Grant | – | – | – |
| May 2021 | – | Grant | – | – | |
| Feb 2021 | – | Post-IPO | – | – | – |
| Jun 2020 | $105.75M | Post-IPO | – | – | – |
| Jun 2001 | – | Private Equity Round | – | – |
3 investors in total: 3 institutional.
Investors in Basilea
Basilea has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include CARB-X, HBM Partners and BARDA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Late-stage life sciences investments are managed via VC and PE. | – | hbmpartners.com | Zug, Switzerland | |
Antibiotics, vaccines, and diagnostics against drug-resistant bacteria are developed. | 2016 | carb-x.org | Boston, United States | |
- | – | medicalcountermeasures.gov | - |
Investor details for Basilea
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Basilea
45 people are tracked at Basilea (23 in leadership, 6 in board & advisors, 16 in team); the tracked headcount is 164.
| Name | Role | Group |
|---|---|---|
Marc Engelhardt | Chief Medical Officer | Leadership |
Laurenz Kellenberger | Chief Scientific Officer | Leadership |
David Veitch | CEO | Leadership |
Anand R. | Global Head Of Drug Safety | Leadership |
Sabine Pierau | Head Of Chemical Development & Production | Leadership |
Ursula Eberhardt | Head, Global Human Resources | Leadership |
Adesh Kaul | CFO | Leadership |
Gerrit Hauck | Chief Technology Officer | Leadership |
Ajay Sapra | Teamleader IT Business Partner | Leadership |
Karine Litherland | Head Of Translational Development | Leadership |
Jonathan Thwaite | Head Of Intellectual Property | Leadership |
Ralf Romain | Head Of Controlling | Leadership |
Michael von Allmen | Head Of Finance | Leadership |
Carolin Siegel | Assistant Chief Medical Officer | Leadership |
Guy Maggay | Head Of IT | Leadership |
Tatjana Soltmannowski | Executive Assistant To CEO & CFO | Leadership |
Stephen Keech Msc | Non-clinical Safety Head | Leadership |
Malcolm Page | Head Of Biology | Leadership |
Mohammed Benghezal | Head Of Biology | Leadership |
Dr. Silke Friedmann | Head Of Clinical Operations | Leadership |
25 more people are available in the full profile.
Complete people profiles for Basilea
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Basilea
Basilea is a publicly listed company on the SIX with ticker symbol BSLN in Switzerland, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Mar 2004
- Listed onSWX: BSLN
- Listed entityBasilea Pharmaceutica AG
- Exchange sectorHealth technology
- ISINCH0011432447
- Share price54.80 CHF (+0.55% on the day) · 2026-05-11
- Market capitalisation669,548,916.00 CHF
- Price to earnings18.1
- EPS (diluted, trailing year)3.02 CHF
- Volume (last session)6,479
- Analyst consensusBuy
Financials of Basilea
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 232.4M CHF | 40.2M CHF | 55.3M CHF |
| 2024 | 208.5M CHF | 77.6M CHF | 64.7M CHF |
| 2023 | 157.6M CHF | 10.4M CHF | 22.7M CHF |
| 2022 | 147.8M CHF | 12.2M CHF | 19.4M CHF |
| 2021 | 148.1M CHF | -6.8M CHF | 3.6M CHF |
Detailed financial statements for Basilea
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Basilea
4 dated milestones of Basilea across 27 years, from founding to its latest funding, stage changes and deals.
- Founded Basilea is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Grant, of $6.0M.
Competitors of Basilea
Basilea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insmed, Affinivax, Imvax, Eligo Bioscience and Aridis Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| insmed.com | 1999 | Bridgewater, United States | – | 912 | Developer of small molecule inhibitors for rare lung diseases | |
| affinivax.com | 2013 | Cambridge, United States | $359.49M | 132 | Technology-based conjugate vaccines against infectious diseases are developed. | |
| imvax.com | 2015 | Philadelphia, United States | $203.83M | 50 | Patient-specific cell vaccines for glioma treatment are developed. | |
| eligo.bio | 2014 | Paris, France | $52.26M | – | In vivo gene editing technology is developed for microbiome modulation. | |
| aridispharma.com | 2005 | San Jose, United States | $42.11M | 34 | Provider of human monoclonal antibodies against infectious diseases | |
| gtmedtech.com | 2017 | Tempe, United States | $129.94M | 29 | Medical devices for brain tumor radiation therapy are provided. | |
| maatpharma.com | 2014 | Lyon, France | $42.3M | – | Microbiome therapies are developed for treating intestinal dysbiosis diseases. | |
| lodotherapeutics.com | 2015 | New York, United States | $19.87M | 24 | Developer novel therapeutics to treat resistant infectious diseases and cancers using AI |
Detailed competitors of Basilea
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Basilea
The website of Basilea (basilea.com) receives about 7.8K visits a month and ranks #2,173,854 among all websites worldwide, #2,952 in Biotechnology and Pharmaceuticals.
- Monthly visits7.8K
▼ 25.5% vs previous month
- Unique visitors4.4K
per month
- Global rank#2,173,854
among all websites
- Category rank#2,952
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit1.8
- Average visit34 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Basilea. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| santhera.com | 100% | 12.6K | #3,177,070 | View details | |
galderma.de | galderma.de | 89% | – | #5,463,079 | – |
hermal.de | hermal.de | 89% | – | – | – |
dr-pfleger.de | dr-pfleger.de | 89% | – | #2,876,468 | – |
leo-pharma.de | leo-pharma.de | 89% | – | – | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Basilea
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Basilea
Complete news archive for Basilea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Basilea
10 companies that operate in the same segment as Basilea (Infectious Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 | |
Clinical diagnostics and drug discovery for immune diseases are provided. | 2009 | Seattle, Washington, United States | USD 419.15 M | USD 276.98 M | 619 | |
Vaccines for infectious diseases are developed using cell-free protein synthesis. | 2013 | Foster City, California, United States | USD 347 M | – | 414 | |
Portable PCR diagnostics for infectious diseases are developed. | 2010 | San Jose, California, United States | USD 386.33 M | – | – | |
Developing glucan synthase inhibitors for the treatment of fungal infections. | 1999 | Jersey City, New Jersey, United States | USD 62.65 M | USD 20.6 M | 28 | |
Sherlock Biosciences is focused on molecular diagnostics development. | 2019 | Watertown, United States | USD 111 M | – | 33 | |
Provider of diagnostic solutions for systemic infections | 2016 | San Francisco, California, United States | USD 191.47 M | – | 54 | |
Developer of novel protein-based therapeutics using machine learning and biological engineering | 2018 | Somerville, Massachusetts, United States | USD 693 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Basilea
Basilea was founded in 1999 and raised its 1st funding round 2 years after it was founded.
Basilea is headquartered in Basel, Switzerland. It is registered at Basel, Basel-stadt, Switzerland.
Basilea has 164 employees.
Annual revenue of Basilea is $293.16M as on Dec 31, 2025.
Basilea is engaged in the development and commercialization of innovative pharmaceutical products targeting severe bacterial and fungal infections. The company operates within the healthcare sector, specializing in anti-infectives. Solutions are provided through a portfolio that includes globally recognized brands like Cresemba and Zevtera, alongside a pipeline of novel antibiotics and antifungals such as Ceftibuten-Ledaborbactam and Fosmanogepix. Research and development efforts are supported by strategic funding and partnerships to address critical medical needs of patients worldwide.
Basilea's top competitors include Imvax, Aridis Pharma and Insmed.
Basilea offers Cresemba, Zevtera, Ceftibuten-Ledaborbactam, Fosmanogepix, and BAL2062.
Yes, Basilea is publicly traded on SIX under the ticker symbol BSLN.
Basilea has 3 investors. Key investors include CARB-X, HBM Partners, and BARDA.
Basilea operates through Basilea Pharmaceutica Ltd.